KLDO News

The US's #2 ridesharing app has finally shared its financials. Lyft filed publicly for an IPO that we estimate could raise $3 billion. The "decacorn" booked $2.2 billion in revenue during 2018, a 103% gain over 2017. Meanwhile, losses swelled to about $1 billion. Two...read more

Kaleido Biosciences, an early-stage biotech developing oral microbiome therapies, raised $75 million by offering 5 million shares at $15, below the range of $20 to $22. The company had originally planned to raise $100 million by offering 4.8 million shares. Kaleido Biosciences plans to list on the Nasdaq under the symbol KLDO. Goldman Sachs, J.P. Morgan and Morgan Stanley acted as...read more

Two IPOs and a SPAC plan to raise a combined $350 million in the week ahead. Several companies may launch March IPOs, including cardiovascular disease device maker ShockWave Medical (SWAV), Diamondback midstream services unit Rattler Midstream LP (RTLR), Chinese online brokerage Futu Holdings (FHL), and NASH biotech...read more

Kaleido Biosciences, an early-stage biotech developing microbiome therapies for rare genetic disorders, announced terms for its IPO on Tuesday. The Lexington, MA-based company plans to raise $100 million by offering 4.8 million shares at a price range of $20 to $22. At the midpoint of the proposed range, Kaleido Biosciences would command a fully diluted market value of $709...read more